XERS Xeris Biopharma

Xeris (XERS) to present Recorlev, Gvoke and XP-8121 data at 2026 CRC, CMHC and ATA meetings

Xeris will present new real-world data on Recorlev (levoketoconazole) for Cushing’s syndrome at the Cardiometabolic Health Congress on October 15-16 2026, including a case study on cortisol normalization and cardiometabolic improvements. Additional presentations cover Gvoke for severe hypoglycemia and a TriNetX analysis on levothyroxine/TSH in hypothyroidism.

Xeris initiates Phase 3 Cornerstone trial for XP-8121 in hypothyroidism

Xeris disclosed that the Cornerstone Phase 3 study of once-weekly subcutaneous XP-8121 is expected to begin by year-end 2026, fully aligned with prior FDA feedback on endpoints and statistical power. The trial will enroll 500 well-controlled adults and adolescents across >50 U.S. sites, with topline data anticipated in late 2028 and potential NDA filing and launch targeted for 2030.